Vitroscope raises $7M to turn living human tissue into a new source of drug discovery data

Vitroscope raised $7 million comprising a $5 million seed round led by Cerberus Ventures and YZR Capital plus $2 million in non-dilutive funding from Norway's Research Council. The company has now raised $8.8 million total. Vitroscope's automated perfusion platform maintains controlled flow and oxygen conditions through living tissue models, enabling longer experiments and richer data collection compared to static well plates. The platform supports organoid and fresh human tissue research for drug discovery applications.

Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. Tech.eu did the reporting; read the original for the full story.